Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 48, 2018 - Issue 6
Submit an article Journal homepage
606
Views
14
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes

Toshito NakagawaChugai Pharmaceutical Co. Ltd., Gotemba, Japan, Correspondence[email protected]
,
Stephen FowlerNon-Clinical Drug Safety, F. Hoffmann-La Roche Ltd., Basel, Switzerland,
,
Kenji TakanashiChugai Pharmaceutical Co. Ltd., Gotemba, Japan,
,
Kuresh YoudimNon-Clinical Drug Safety, F. Hoffmann-La Roche Ltd., Basel, Switzerland,
,
Tsuyoshi YamauchiChugai Pharmaceutical Co. Ltd., Gotemba, Japan,
,
Kosuke KawashimaChugai Pharmaceutical Co. Ltd., Gotemba, Japan,
,
Mika Sato-NakaiChugai Pharmaceutical Co. Ltd., Gotemba, Japan,
,
Li YuRoche Innovation Center, New York, NY, USA
&
Masaki IshigaiChugai Pharmaceutical Co. Ltd., Gotemba, Japan,
show all
Pages 546-554 | Received 18 Apr 2017, Accepted 17 Jun 2017, Published online: 21 Jul 2017

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Mizuki Yamane, Fumihiko Igarashi, Tsuyoshi Yamauchi & Toshito Nakagawa. (2021) Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout. Xenobiotica 51:1, pages 61-71.
Read now

Articles from other publishers (13)

Ya-nan Liu, Jie Chen, Jing Wang, Qingqing Li, Guo-xin Hu, Jian-ping Cai, Guanyang Lin & Ren-ai Xu. (2023) Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism. Archives of Toxicology 97:8, pages 2133-2142.
Crossref
R. Dziadziuszko, S. Peters, T. Ruf, A. Cardona, E. Guerini, N. Kurtsikidze, V. Smoljanovic & D. Planchard. (2022) Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib. ESMO Open 7:6, pages 100612.
Crossref
Qi Zhao, Zhanxuan E. Wu, Bin Li & Fei Li. (2022) Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Pharmacology & Therapeutics 237, pages 108256.
Crossref
Joy C. Hsu, Felix Jaminion, Elena Guerini, Bogdana Balas, Walter Bordogna, Peter N. Morcos & Nicolas Frey. (2021) Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase – positive non‐small cell lung cancer . CPT: Pharmacometrics & Systems Pharmacology 10:11, pages 1357-1370.
Crossref
Mehmet Hadi Akkus, Omur Kaman & Mutlu Dogan. (2021) Alectinib continuation during COVID 19 ‘antiviral’ treatment: Risk or benefit?. Journal of Oncology Pharmacy Practice 27:5, pages 1251-1254.
Crossref
Mo'tasem M. Alsmadi, Nour M AL‐Daoud, Mays M. Jaradat, Saja B. Alzughoul, Amani D. Abu Kwiak, Salam S. Abu Laila, Ayat J. Abu Shameh, Mohammad K. Alhazabreh, Sana'a A. Jaber & Hala T. Abu Kassab. (2021) Physiologically‐based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment. Biopharmaceutics & Drug Disposition 42:6, pages 263-284.
Crossref
Jianyong Chen, Yunlong Zhou, Xuyuan Dong, Liu Liu, Longchuan Bai, Donna McEachern, Sally Przybranowski, Chao-Yie Yang, Jeanne Stuckey, Xiaoqin Li, Bo Wen, Ting Zhao, Siwei Sun, Duxin Sun, Lingling Jiao, Yu Jing, Ming Guo, Dajun Yang & Shaomeng Wang. (2020) Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. Journal of Medicinal Chemistry 63:22, pages 13994-14016.
Crossref
Marie‐Noëlle Paludetto, Florent Puisset, Etienne Chatelut & Cécile Arellano. (2019) Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity. Medicinal Research Reviews 39:6, pages 2105-2152.
Crossref
Jakub Hofman, Ales Sorf, Dimitrios Vagiannis, Simona Sucha, Eva Novotna, Sarah Kammerer, Jan-Heiner Küpper, Martina Ceckova & Frantisek Staud. (2019) Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metabolism and Disposition 47:7, pages 699-709.
Crossref
Ken-ichi Fujita, Natsumi Matsumoto, Hiroo Ishida, Yutaro Kubota, Shinichi Iwai, Motoko Shibanuma & Yukio Kato. (2019) Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure. Current Drug Metabolism 20:5, pages 361-376.
Crossref
Pramod C. Nair, Ross A. McKinnon & John O. Miners. (2019) Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4. Drug Metabolism and Disposition 47:6, pages 616-631.
Crossref
Takeshi Hirota, Shota Muraki & Ichiro Ieiri. (2018) Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. Clinical Pharmacokinetics 58:4, pages 403-420.
Crossref
Julia Paik & Sohita Dhillon. (2018) Alectinib: A Review in Advanced, ALK-Positive NSCLC. Drugs 78:12, pages 1247-1257.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.